Member access

4-Traders Homepage  >  Shares  >  Nasdaq  >  Alnylam Pharmaceuticals, Inc.    ALNY   US02043Q1076

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
03/23/2015 03/24/2015 03/25/2015 03/26/2015 03/27/2015 Date
111.49(c) 110.06(c) 101.78(c) 99.64(c) 104.06(c) Last
895 307 644 878 787 734 768 495 850 061 Volume
-5.08% -1.28% -7.52% -2.10% +4.44% Change
More quotes
Financials ($)
Sales 2015 52,3 M
EBIT 2015 -254 M
Net income 2015 -236 M
Finance 2015 808 M
Yield 2015 -
Sales 2016 54,8 M
EBIT 2016 -262 M
Net income 2016 -269 M
Finance 2016 639 M
Yield 2016 -
PER 2015 -
PER 2016
EV / Sales 2015 152x
EV / Sales 2016 148x
Capitalization 8 740 M
More Financials
Company
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which develops novel therapeutics based on RNA interference.It is leading the translation of RNAi as a new class of innovative medicines with a core focus on RNAi therapeutics for the treatment of genetically defined diseases, including... 
More about the company
Surperformance© ratings of Alnylam Pharmaceuticals, I
Trading Rating : Investor Rating :
More Ratings
Latest news on ALNYLAM PHARMACEUTICALS, I
03/26 ALNYLAM PHARMACEUTICALS : Assigned Patent
03/25 ALNYLAM PHARMACEUTICALS : Presents Results from Natural History Study of Patient..
03/16 ALNYLAM PHARMACEUTICALS : Announces Results From History Study Of Patients With ..
03/15 ALNYLAM PHARMACEUTICALS : Presents Results from Natural History Study of Patient..
03/13 ALNYLAM PHARMACEUTICALS : to Webcast Presentation at 22nd Annual Future Leaders ..
03/13 ALNYLAM PHARMACEUTICALS : Assigned Patent
03/11 ALNYLAM PHARMACEUTICALS : Schedules Webcast Presentation at Barclays Global Heal..
03/05 ALNYLAM PHARMACEUTICALS : to Webcast Presentation at Barclays Global Healthcare ..
More news
Sector news : Biotechnology & Medical Research - NEC
03/27 ISIS PHARMACEUTICALS : Earnings Coverage - Isis Pharma
03/26 Alliance invokes Elliott track record in appeal against board shake-up
03/26 ACTELION : receives marketing approval for Opsumit (macitentan) in pulmonary art..
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
03/05 Arrowhead buys Novartis' RNAi assets
02/27 Biogen's hemophilia B med successful in Phase 3 trial in children
02/13 Alnylam Pharma ups revenues 122% in Q4
02/12 Alnylam Pharmaceuticals' (ALNY) CEO John Maraganore on Q4 2014 Results - Earn..
02/12 Alnylam Pharmaceuticals (ALNY) Q4 2014 Results - Earnings Call Webcast


Comments 
Advertisement
Chart ALNYLAM PHARMACEUTICALS, I
Duration : Period :
Alnylam Pharmaceuticals, I Technical Analysis Chart | ALNY | US02043Q1076 | 4-Traders
Full-screen chart
Technical analysis trends
Short TermMid-TermLong Term
TrendsBearishBullishBullish
Technical analysis
Income Statement Evolution
More Financials
EPS Revisions
More Estimates Revisions
Dynamic quotes  
ON
| OFF